Pharmacokinetic Evaluation and Short-Term Activity of Stavudine, Nevirapine, and Nelfinavir Therapy in HIV-1???Infected Adults
- 1 April 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 35 (4), 351-358
- https://doi.org/10.1097/00126334-200404010-00004
Abstract
Evaluate pharmacokinetic interaction, short-term safety, and antiretroviral activity of stavudine (d4T), nevirapine (NVP), and nelfinavir (NFV) as combination HIV-1 therapy. Prospective, open-label study investigating the pharmacokinetic interactions between d4T, NVP, and NFV and documenting short-term tolerability and virologic and immunologic activity. Twenty-five HIV-1-infected adults, naive to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), ≤6 months of d4T treatment, CD4 ≥100 cells/mm3, and viral load ≥5,000 copies/mL enrolled. All received NFV 750 mg 3 times daily and d4T 30–40 mg twice daily for 1 week, then added NVP at 200 mg once daily for 2 weeks and 200 mg twice daily thereafter. Steady-state pharmacokinetic parameters of NFV, AG1402 (metabolite of NFV), and d4T were compared before and after the addition of NVP. No statistically significant changes in NFV or d4T pharmacokinetics were observed following the addition of NVP. Levels of AG1402 were suppressed 60–70%. Drug-related adverse events were seen at expected rates. At day 36, median viral load suppression was 2.0 log10 and absolute CD4 count increased by 111 cells/mm3. NVP administration did not significantly affect the steady-state pharmacokinetic parameters of NFV or d4T. The combination of d4T, NVP, and NFV induced rapid suppression of HIV-1 viral load and rises in CD4 cell count.Keywords
This publication has 23 references indexed in Scilit:
- Antiretroviral Treatment for Adult HIV Infection in 2002JAMA, 2002
- Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment FailureA Randomized TrialJAMA, 2002
- Baseline CD4 + Cell Count, Not Viral Load, Correlates With Virologic Suppression Induced by Potent Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral ActivitiesAntimicrobial Agents and Chemotherapy, 2001
- A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus-Infected Patients Enrolled in a Phase III Clinical TrialAntimicrobial Agents and Chemotherapy, 2000
- CD4 Lymphocyte Count as a Predictor of the Duration of Highly Active Antiretroviral Therapy–Induced Suppression of Human ImmunodeficiencyVirus LoadThe Journal of Infectious Diseases, 1999
- Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic OutcomeThe Journal of Infectious Diseases, 1999
- HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapyAIDS, 1999
- Lack of pharmacokinetic interaction between nelfinavir and nevirapineAIDS, 1998
- Clinical Pharmacokinetics of StavudineClinical Pharmacokinetics, 1997